<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="508">
  <stage>Registered</stage>
  <submitdate>8/12/2004</submitdate>
  <approvaldate>8/12/2004</approvaldate>
  <nctid>NCT00098878</nctid>
  <trial_identification>
    <studytitle>Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</studytitle>
    <scientifictitle>SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CDR0000396778</secondaryid>
    <secondaryid>SCOTTISH-SCOTROC-4</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fallopian Tube Cancer</healthcondition>
    <healthcondition>Ovarian Cancer</healthcondition>
    <healthcondition>Primary Peritoneal Cavity Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - carboplatin

Treatment: drugs: carboplatin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical overall response rate and CA125 response</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal
             cancer*

               -  Stage IC-IV disease

               -  Peritoneal carcinomatosis* (ovarian-type) must not be a mucin-secreting tumor

               -  Stage IC patients must have malignant cells in ascitic fluid or peritoneal
                  washings, tumor on the surface of the ovary, or preoperative capsule rupture
                  NOTE: * Histologic confirmation of a primary source in the ovary is not required.

          -  If biospy is not available, cytology showing an adenocarcinoma is allowed provided the
             following criteria is met:

               -  Patient has a pelvis (ovarian) mass AND all of the following:

                    -  Omental cake or other metastasis is larger than 2 cm in the upper abdomen
                       and/or regional lymph node metastasis irrespective of size OR stage IV
                       disease

                    -  Serum CA 125/CEA ratio &gt; 25 or barium enema (or colonoscopy) and gastroscopy
                       (or radiological examination of the stomach) are negative for the presence
                       of a primary tumor and normal mammography within 6 weeks prior to study
                       randomization

          -  Initial cytoreductive laparotomy or biopsy required within the past 8 weeks

               -  Cytoreductive surgery may or may not have been successful during staging
                  laparotomy

          -  No mixed mesodermal tumors

          -  No borderline ovarian tumors or tumors termed "possibly malignant"

          -  No adenocarcinoma of unknown origin, if histologically confirmed to be a
             mucin-secreting tumor

          -  Considered unsuitable for or unwilling to receive platinum-taxane combination therapy

          -  No concurrent endometrial cancer

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-3

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count = 1,500/mm^3

          -  Platelet count = 100,000/mm^3

        Hepatic

          -  Bilirubin normal

          -  AST and ALT = 2.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase = 5 times ULN

        Renal

          -  Creatinine clearance = 30 mL/min

               -  Obstructive hydronephrosis as a cause of borderline (i.e., creatinine clearance
                  30-45 mL/min) renal function must be treated before study entry

        Cardiovascular

          -  No hypertension

          -  No ischemic heart disease

          -  No myocardial infarction within the past 6 months

          -  No congestive heart failure

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No symptomatic peripheral neuropathy = grade 2

          -  No uncontrolled infection

          -  No other severe and/or uncontrolled medical condition

          -  No other malignancy within the past 5 years except curatively treated carcinoma in
             situ of the cervix or basal cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

          -  No other concurrent cytotoxic chemotherapy until progressive disease occurs

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  See Disease Characteristics</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC</recruitmentstate>
    <hospital>Sydney Heamatology and Oncology Clinics - Hornsby</hospital>
    <hospital>Lismore Base Hospital - Lismore</hospital>
    <hospital>Institute of Oncology at Prince of Wales Hospital - Randwick</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Sydney Cancer Centre at Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Tamworth Base Hospital - Tamworth</hospital>
    <hospital>Manning Base Hospital - Taree</hospital>
    <hospital>Newcastle Mater Misericordiae Hospital - Waratah</hospital>
    <hospital>Westmead Institute for Cancer Research at Westmead Hospital - Wentworthville</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Townsville Hospital - Douglas</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Ballarat Oncology and Haematology Services - Ballarat</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Royal Women's Hospital - Carlton</hospital>
    <hospital>Monash Medical Center - Clayton Campus - Clayton</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>Mercy Hospital for Women - Heidelberg</hospital>
    <hospital>Murray Valley Private Hospital and Cancer Treatment Centre - Wodonga</hospital>
    <postcode>2077 - Hornsby</postcode>
    <postcode>2480 - Lismore</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2340 - Tamworth</postcode>
    <postcode>2430 - Taree</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4814 - Douglas</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3350 - Ballarat</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3690 - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northern Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wales</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>NHS Greater Glasgow and Clyde</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.

      PURPOSE: This randomized phase III trial is comparing different doses of carboplatin to see
      how well they work in treating patients with stage IC, stage II, stage III, or stage IV
      ovarian, fallopian tube, or primary peritoneal cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00098878</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stanley B. Kaye, MD, FRCP</name>
      <address>Royal Marsden NHS Foundation Trust</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>